Foundation For Angelman Syndrome Therapeutics
- Assets
- $63.1m
- Revenue
- $52.5m
- Investments
- $1.1m
- Employees
- 8
- Location
- Austin, TX
- Founding
- 12/2008
- Data as of
- 12/2022
- EIN
- 26-3160079
Organization Overview
Foundation For Angelman Syndrome Therapeutics is located in Austin, TX. The organization was established in 2008. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. As of 12/2022, Foundation For Angelman Syndrome Therapeutics employed 8 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Foundation For Angelman Syndrome Therapeutics is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Foundation For Angelman Syndrome Therapeutics generated $52.5m in total revenue. This organization has experienced exceptional growth, as over the past 7 years, it has increased revenue by an average of 42.5% each year . All expenses for the organization totaled $8.9m during the year ending 12/2022. While expenses have increased by 14.6% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2014, Foundation For Angelman Syndrome Therapeutics has awarded 44 individual grants totaling $21,661,401. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) IS DEDICATED TO FINDING A CURE FOR ANGELMAN SYNDROME (AS) AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGGRESSIVE RESEARCH AGENDA, EDUCATION, AWARENESS, AND ADVOCACY.
Describe the Organization's Program Activity:
Part 3 - Line 4a
FAST'S PRIMARY GOAL IS TO ADVANCE RESEARCH LEADING TO A CURE FOR AS IN THE FORM OF PROVIDING GRANTS TO UNIVERSITIES TO PERFORM RESEARCH AND TESTING.
AS IS A RARE DISORDER. THE COMMUNITY OF PARENTS AND CAREGIVERS OF INDIVIDUALS WITH AS RELY HEAVILY ON SOCIAL NETWORKING TO BECOME INFORMED AND SEEK ADVICE AND GUIDANCE ON THE CHALLENGES WHICH THE DISORDER PRESENTS. IT IS ONE OF FAST'S OBJECTIVES TO EDUCATE, SUPPORT, AND STRENGTHEN THIS COMMUNITY.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
John Schuellter Chairperson | OfficerTrustee | 30 | $0 |
Kelly David Co-Vice Chairperson | OfficerTrustee | 30 | $0 |
Kristy Dixon Co-Vice Chairperson And Treasurer | OfficerTrustee | 25 | $0 |
Ben O'connor Director | OfficerTrustee | 5 | $0 |
Allyson Berent Chief Science Officer | Trustee | 40 | $0 |
Roy Azout Director | Trustee | 5 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
As2 Biotherapeutics Llc Consulting Services | 12/30/22 | $246,108 |
Medicus Economics Llc Develop A Payer And Reimbursement Strate | 12/30/22 | $174,740 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $2,787,000 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $2,161,249 |
| Noncash contributions included in lines 1a–1f | $100,755 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $4,948,249 |
| Total Program Service Revenue | $355,507 |
| Investment income | $508,992 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $47,271,158 |
| Net Income from Fundraising Events | -$606,087 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $52,477,819 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $6,744,524 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $485,109 |
| Compensation of current officers, directors, key employees. | $193,203 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $408,158 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $36,373 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $258,494 |
| Fees for services: Accounting | $24,665 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $38,460 |
| Fees for services: Other | $31 |
| Advertising and promotion | $328,839 |
| Office expenses | $11,879 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $119,811 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $14,584 |
| Insurance | $2,844 |
| All other expenses | $82,805 |
| Total functional expenses | $8,933,021 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $54,308,955 |
| Savings and temporary cash investments | $4,283,216 |
| Pledges and grants receivable | $2,316,785 |
| Accounts receivable, net | $237,629 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $14,584 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $1,134,755 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $779,430 |
| Total assets | $63,075,354 |
| Accounts payable and accrued expenses | $226,506 |
| Grants payable | $7,033,207 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $7,259,713 |
| Net assets without donor restrictions | $55,800,184 |
| Net assets with donor restrictions | $15,457 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $63,075,354 |
Grants Awarded
Over the last fiscal year, Foundation For Angelman Syndrome Therapeutics has awarded $800,071 in support to 4 organizations.
| Grant Recipient | Amount |
|---|---|
TEXAS A&M UNIVERSITY PURPOSE: TRANSLATIONAL RESEARCH IN PIG MODEL OF AS | $277,778 |
YALE UNIVERSITY PURPOSE: GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A | $233,299 |
UNIVERSITY OF PENNSYLVANIA PURPOSE: A. THE UBE3A ANTISENSE TRANSCRIPT (UBE3A-AS) IS A LONG NON-CODING MRNA THAT SILENCES EXPRESSION OF THE PATERNAL UBE3A GENE IN NEURONS. INTERRUPTION OF THIS IMPRINTING PHENOMENON CAN BE DONE THROUGH ASOS, CRISPR-GRNA OR OTHER TECHNOLOGIES LIKE MICRORNA (MIRNA). THIS PROJECT IS AIMING TO DEVELOP A STRATEGY TO SUPPRESS THE UBE3A-AS IN THE MOUSE MODEL OF AS USING MIRNAS. ADVANTAGES TO MIRNA ARE THAT THEY ARE SUBJECT TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION, WHICH CAN HELP CIRCUMVENT ISSUES RELATED TO OVEREXPRESSION OF EXOGENOUS GENETIC MATERIAL (WITH UBE3A REPLACEMENT), AND THE NEED FOR REPEATED REDOSING (WITH ASOS). MIRNA IS THOUGHT TO BE ADVANTAGEOUS OVER SHRNA DUE TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION COMPARED TO OVEREXPRESSION YOU COULD GET WITH SHRNA. | $115,121 |
NORTH CAROLINA STATE UNIVERSITY PURPOSE: BANDODKAR LAB HUMAN ORGANOID ARRAYS TO STUDY AS | $173,873 |